Time will determine the shape of biosimilar usage in oncology, but they will play a significant role in the battle against cancer in the future, writes Alessandra Franceschetti.
Alessandra Franceschetti
Advertisement
Alessandra Franceschetti is Associate Director, Oncology Real World Evidence, Ipsos Healthcare.
Articles by Alessandra Franceschetti
Advertisement
Latest Updated Articles
mAb Biosimilars: The Future of Cancer Treatment?Published: July 31st 2017 | Updated:
Advertisement
Advertisement
